Viveve Medical, Inc. (VIVE): Business Model Canvas [Dec-2025 Updated]

You're likely looking at the ticker for Viveve Medical, Inc. expecting to see a growth story, but after the Chapter 7 bankruptcy, the business model is, frankly, a liquidation map. Honestly, as an analyst who's seen a few of these wind-downs, the canvas today reflects a non-operational entity where operational revenue for the 2025 fiscal year is effectively $0, and the market cap hovers around a nominal $4.3K. We're not analyzing product-market fit here; we're detailing the final administrative structure, key partners like the Chapter 7 Trustee and InMode Ltd., and the cost structure dedicated only to winding down. Dive into the details below to see exactly how the remaining shell is structured for its creditors and distressed asset investors.

Viveve Medical, Inc. (VIVE) - Canvas Business Model: Key Partnerships

You're looking at the final stage of a business, so the Key Partnerships section of the Business Model Canvas for Viveve Medical, Inc. as of late 2025 isn't about growth or co-development; it's about legal closure. Honestly, the operational business model ceased to exist when the core assets were sold. What remains are the entities required to manage the liquidation under court supervision.

The most significant 'partnership' was the sale of the core technology. InMode Ltd. stepped in to acquire the Intellectual Property (IP) assets, which included all of Viveve Medical, Inc.'s worldwide patents. This transaction for the IP assets was completed on July 25, 2023, though the sale of core system assets followed in early 2024 after the Chapter 11 filing in May 2023 converted to a Chapter 7 liquidation. As of November 2025, the entity trades with a market capitalization of approximately $4.29 thousand USD, a stark contrast to the $6.82 Million USD Trailing Twelve Months revenue reported before the wind-down.

The entire process is governed by the judicial system, which dictates the final distribution to creditors. The Bankruptcy Court confirmed the Plan on April 24, 2025, with an Effective Date of the Plan occurring on May 12, 2025. This confirmation set the final administrative deadlines.

Here's a breakdown of the key players involved in this wind-down structure:

The administrative structure required strict adherence to court-ordered timelines for any remaining parties to assert claims against the estate. The focus shifted entirely to fulfilling the requirements set forth by the court for the final distribution.

The critical administrative deadlines that defined the final phase of the estate's activity were:

• Bid Deadline for Assets: January 24, 2025 at 4:00 p.m. (MT)
• General Bar Date for Claims: April 14, 2025
• Administrative Claims Bar Date: April 14, 2025
• Governmental Bar Date: June 9, 2025

To be fair, the only remaining 'value' proposition these partnerships represent is the orderly winding down of liabilities, which is a far cry from the original business goal of selling the Viveve System for treating stress urinary incontinence (SUI). Finance: confirm the final administrative expense accruals against the May 12, 2025 Effective Date for the final report.

Viveve Medical, Inc. (VIVE) - Canvas Business Model: Key Activities

You're looking at the Key Activities for Viveve Medical, Inc. (VIVE) as of late 2025. Honestly, the primary activities are no longer about selling the Viveve System or driving procedure volumes; the company is in a Chapter 7 liquidation phase following the asset sale to InMode Ltd. in early 2024. The focus has completely shifted to closing the books on the former operating entity.

Administrative wind-down and final legal compliance

The core activity here involves fulfilling all remaining statutory and regulatory obligations for a non-operational entity. This is the necessary cleanup after the Chapter 11 filing in 2023 and the subsequent asset sale. You need to ensure all post-acquisition legal loose ends are tied up. The company's operational revenue for the 2025 fiscal year is effectively $0 (zero), which underscores the nature of these final administrative tasks.

• Finalizing all required disclosures for the Expert Market (PINK) listing.
• Completing all necessary filings related to the Chapter 7 proceedings.
• Terminating all remaining vendor and service contracts.

Managing the remaining nominal cash balance and liabilities

This activity centers on reconciling the final balance sheet items. You're dealing with what's left after the core business was sold off. To give you a sense of the scale of the entity being managed, the latest reported total assets stood at $12.15 million, against total liabilities of $10.84 million in the last reported quarter. The equity value remaining for distribution is what's left after these obligations are settled. The stock itself reflects this shell status, trading for approximately $0.0001 with a market capitalization around $4.29 thousand as of December 4, 2025.

Here's a quick look at the financial context of the shell entity:

The Debt / Equity ratio was reported at 507.94% previously, which highlights the significant creditor claims that must be addressed before any residual distribution.

Filing final financial reports for the non-operational entity

This involves preparing and submitting the final required financial statements to the SEC and other stakeholders, reflecting the cessation of operations. Since the company is no longer a going concern, these reports detail the liquidation status rather than operational performance. The last reported Trailing Twelve Months (TTM) revenue before the operational wind-down was $6.82 Million USD. You must ensure the final reports clearly show the disposition of assets and settlement of liabilities. The accumulated deficit as of September 2017 was approximately $95.4 million, which provides historical context for the final accounting.

• Preparing the final 10-K or equivalent filing detailing the wind-down.
• Reconciling all cash and cash equivalents against final operational expenses.
• Auditing the final accounting entries related to the asset sale.

Facilitating the final distribution of any residual assets to creditors

This is the final, critical step: paying out what is legally owed to creditors based on the priority established in the bankruptcy proceedings. Any amount remaining after all secured and unsecured creditors are satisfied is what might, theoretically, flow to equity holders, though given the historical deficit, this is unlikely for common shareholders. The stock's 5-year price decrease of 100.00% suggests minimal, if any, residual value for equity. The activity involves coordinating with the bankruptcy trustee to execute the final distribution schedule.

The key steps involve:

• Verifying the final allowed claims from all creditors.
• Calculating the final pro-rata distribution percentages for each class of creditor.
• Executing the final cash transfers from the remaining nominal cash balance.

Finance: draft the final distribution ledger by next Tuesday.

Viveve Medical, Inc. (VIVE) - Canvas Business Model: Key Resources

You're looking at the remnants of a business, so the Key Resources section is less about what drives current operations and more about what remains after the core asset sale and liquidation process.

The most significant resource, the core technology, is no longer a Viveve Medical, Inc. asset. The entity itself is now primarily a shell undergoing final administrative wind-down.

Legacy intellectual property now owned by InMode Ltd.

• All worldwide patents were transferred to InMode Ltd. on July 25, 2023.
• The IP acquisition fortified InMode Ltd. as the global market leader in women's wellness products development.

The publicly traded VIVE ticker on the Expert Market (OTCPK)

The trading data reflects the status of the residual, non-operating legal entity as of late 2025, post-asset sale and bankruptcy proceedings.

Nominal cash balance remaining in the corporate shell

A precise, current nominal cash balance for the shell as of late 2025 was not publicly itemized in the latest available data points. The closest indication of the shell's public financial footprint is its market capitalization, which stood at approximately $1.08K as of today in November 2025. The entity is in a Chapter 7 liquidation phase.

Remaining legal entity structure for administrative purposes

The structure is defined by its liquidation status following Chapter 11 bankruptcy in late 2023, converted to Chapter 7.

• Status: Chapter 7 liquidation wind-down phase.
• Equity Holders: Effectively wiped out.
• Probability of Bankruptcy: Cited as 100% for the residual stock.

The company is no longer an operating business. Finance: draft 13-week cash view by Friday.

Viveve Medical, Inc. (VIVE) - Canvas Business Model: Value Propositions

The current Value Propositions for Viveve Medical, Inc. (VIVE) reflect a post-operational, distressed asset entity, not a going concern providing medical device solutions.

None for former customers; the business is non-operational

The core value proposition of providing non-invasive treatment for conditions like vaginal introital laxity and sexual function ceased following the failure of the pivotal U.S. PURSUIT Trial for Stress Urinary Incontinence (SUI) around January 2023. The company subsequently decided to delist from Nasdaq and explore strategic options, including a sale of assets or a wind-down of operations. The entity that existed to serve customers is no longer active.

• The last reported employee count was 47 employees.
• The company's primary product, the Viveve System, is no longer actively marketed or supported by the original entity.
• The business model pivot in 2023 involved ceasing pursuit of FDA registration for the SUI treatment.

Finality and closure for creditors and the bankruptcy estate

The financial metrics as of late 2025 indicate that any remaining corporate structure is a minimal shell, which is consistent with the final stages of asset realization or liquidation following the operational cessation in 2023 and subsequent asset sale in July 2023. The value proposition here is the final, albeit minimal, distribution or settlement for remaining stakeholders.

Here's the quick math on the current market valuation, which speaks to the residual value for the estate:

What this estimate hides is the actual quantum of outstanding creditor claims versus the proceeds from the asset sales, which would be detailed in final bankruptcy court filings, not public trading data. The trading price of $0.0001 suggests negligible equity value remaining for distribution after secured claims. The last reported EPS (TTM) was -$2.65.

A nominal trading vehicle for distressed asset investors

For investors, the value proposition is purely speculative, centered on the residual value of the publicly traded shell on the OTC Markets (OTCMKTS) under the ticker VIVE. This is a vehicle for trading highly illiquid, low-priced securities.

• The stock trades on the OTC Markets stock exchange.
• The average daily trading volume over the last 3 months was reported as 15,466 shares, though other reports show volumes as low as 0 or 0.16K on specific days in November 2025.
• The stock has undergone 4 stock splits historically.

The trading activity itself is minimal, with the stock price showing zero change on several recent trading days in early December 2025, hovering at $0.0001. Finance: draft 13-week cash view by Friday.

Viveve Medical, Inc. (VIVE) - Canvas Business Model: Customer Relationships

You're looking at the Customer Relationships block for Viveve Medical, Inc. (VIVE) as of late 2025. Honestly, the picture here is stark; the relationship is no longer commercial, it's purely administrative and legal.

None; the company ceased all commercial operations

The core of the customer relationship structure dissolved when Viveve Medical, Inc. ceased independent commercial operations. This means all prior relationships with patients, physicians, and distribution partners have been terminated or transferred to the acquirer of the assets following the bankruptcy process. The company's last reported revenue, for instance, was approximately $6.43 million in 2021, which is now historical data, not a current revenue stream. The entity, as a going concern, has no active customer base to manage.

The final state of the equity relationship, which represents the former relationship with shareholders, is reflected in the stock's trading status as of December 4, 2025. The Market Cap stood at a mere $38.60K, with the stock price hovering near zero.

Formal communication with the Chapter 7 Trustee and legal counsel

Customer relationship management has been entirely replaced by formal, legally mandated communication channels. This is the only remaining interaction with stakeholders who might have had a prior relationship with Viveve Medical, Inc. The communication is managed under the supervision of the Chapter 7 Trustee, who oversees the liquidation of the debtor's estate.

The nature of these interactions is governed by the Bankruptcy Code, specifically Chapter 7. You'd expect to see formal notices sent out regarding:

• The status of asset sales, such as the Intellectual Property Assets acquired by InMode Ltd..
• Deadlines for filing proofs of claim by creditors.
• Distribution schedules for any realized proceeds.

The administrative process is overseen by the U.S. Trustee Program, which supervises private trustees in their respective judicial districts, as of January 15, 2025.

Minimal administrative contact with former vendors/creditors

For former vendors and creditors, the relationship is now strictly administrative, focused on the claims process. This is a necessary step to resolve outstanding liabilities from before the cessation of operations. The focus is on processing claims against the estate, not on ongoing service or support.

Here's a look at the financial context surrounding these former relationships, based on the last available pre-liquidation figures, which frame the scale of the administrative task:

Any ongoing contact involves the Trustee's office ensuring due process for unsecured creditors. If onboarding takes 14+ days, churn risk rises-though here, the 'churn' is the finality of the claim resolution.

Finance: draft the final claims reconciliation ledger based on the Trustee's latest notice by next Tuesday.

Viveve Medical, Inc. (VIVE) - Canvas Business Model: Channels

You're looking at the channels for Viveve Medical, Inc. (VIVE) as of late 2025. Honestly, the channels for an operating medical device company are completely gone. The reality is that the primary channel now is the legal and financial system dealing with the residual shell of the entity.

None; no products or services are being sold

The core business channel-selling the Viveve System and recurring disposable treatment tips-ceased operations. The company's key assets, including the technology platform, were acquired by InMode Ltd. in early 2024 following the Chapter 11 bankruptcy filing in late 2023, which converted to a Chapter 7 liquidation. Therefore, the channel for generating revenue from product sales is defunct.

To give you context on the former sales channels, which involved direct sales employees and distributors across the United States, Canada, Asia Pacific, Europe, the Middle East, and Latin America, here is a look at the last reported operational financial snapshot versus the current shell status:

Legal filings and public disclosures via the bankruptcy court system

The main conduit for official information flow now is the bankruptcy court system, which manages the wind-down process. This channel is critical for any remaining stakeholders, including former shareholders, to track administrative actions. You won't find product updates here, but you will find filings detailing the disposition of assets and liabilities.

The key activities flowing through this channel involve the residual corporate structure:

• Tracking of Chapter 7 liquidation proceedings.
• Disclosures related to the sale of Intellectual Property Assets to InMode Ltd.
• Official notices regarding the cessation of operations.

OTC Expert Market for the trading of the VIVE stock

The stock ticker VIVE remains active, trading on the OTC Expert Market (PINK), which is the channel for the residual security. Trading activity is extremely thin, reflecting the non-operational status of the underlying business. You should definitely note the difference between the historical volume and what you see now.

Here's what the trading data shows as of early December 2025:

The trading channel is purely speculative, representing the shell; the institutional percentage held is minimal at only 0.30%. Insider Percentage Owned stands at 27.8%, though recent insider activity is non-existent in the last 90 days.

Finance: draft a memo to the remaining board members detailing the implications of the $0.000100 trading price on any final shareholder distribution plan by next Tuesday.

Viveve Medical, Inc. (VIVE) - Canvas Business Model: Customer Segments

You're looking at the final stakeholders in a company that has moved past its operational phase, so the customer segments are now defined by their financial claims and interest in the remaining shell entity.

The primary groups interacting with the shell stock and residual assets as of late 2025 are not product buyers, but rather financial claimants and speculators.

• Bankruptcy creditors seeking final claim resolution
• Distressed asset investors trading the shell stock
• Former shareholders awaiting final liquidation reports

For the distressed asset investors, the trading activity reflects the minimal residual value left in the entity. Here's a quick look at the market context for the shell stock, VIVE, trading on the OTC Markets Group (OTCMKTS).

The trading volume itself is extremely low, suggesting minimal active interest outside of automated or highly specific residual trades. For instance, one report showed a trading volume of 1,005 shares, compared to an average volume of 15,466 shares over the prior three months.

The former shareholders are focused on the final distribution waterfall, which is dictated by the bankruptcy proceedings and the priority of claims over equity holders. Their segment interest is purely residual, contingent on any funds remaining after secured and unsecured creditors are satisfied.

The market cap figures show a significant decline; one report noted a decrease of -49.88% in market cap over the preceding year. Honestly, the current valuation is a fraction of what it once was, with the stock price having decreased by -100.00% over the past five years from a high point.

Finance: draft 13-week cash view by Friday.

Viveve Medical, Inc. (VIVE) - Canvas Business Model: Cost Structure

The Cost Structure for Viveve Medical, Inc. (VIVE) in a late 2025 wind-down scenario centers on the necessary expenditures to conclude the Chapter 7 process and maintain minimal public status, if applicable.

Minimal administrative and legal fees for the Chapter 7 process are primarily driven by statutory court fees and the initial engagement of legal counsel, though the latter is often minimized post-asset sale.

• Chapter 7 Court Filing Fee (2025 Estimate): $338
• Chapter 7 Administrative Fee (2025 Estimate): $78
• Trustee Surcharge (2025 Estimate): $15

Trustee compensation for overseeing the liquidation is governed by the Bankruptcy Code, which sets a maximum commission based on funds disbursed from the estate to creditors. For a no-asset case, the trustee's compensation is often limited to the initial filing fee portion.

The statutory maximum commission structure for a Chapter 7 Trustee, applicable if assets are distributed, is:

Compliance costs for maintaining the shell entity's public listing on the OTC Pink tier, assuming the entity remains listed post-liquidation to facilitate residual claims or transactions, involve annual service fees to the OTC Markets Group.

• OTC Pink Annual Fee (2025 Rate Proxy): $5,000

These ongoing costs are essential to avoid relegation to less transparent markets like Pink Limited or Expert Market, which can further depress any residual equity value. The actual legal fees for the wind-down, beyond the court-mandated fees, depend heavily on the complexity of settling remaining liabilities and any required SEC filings for the shell entity.

Viveve Medical, Inc. (VIVE) - Canvas Business Model: Revenue Streams

You're looking at the revenue streams for Viveve Medical, Inc. (VIVE) as of late 2025, and honestly, the picture is stark because the operating company is gone.

Operational revenue for the 2025 fiscal year is effectively $0 (zero). This reflects the fact that the core business operations, including the sale of the Viveve System and its consumable tips, ceased following the acquisition of its key assets by InMode Ltd. in early 2024 after the company entered Chapter 11 bankruptcy proceedings in late 2023. The company is no longer generating sales from its intended business model.

Potential final, non-recurring proceeds from the sale of any residual assets are not publicly itemized as a specific 2025 financial figure, as the major asset sale occurred in 2024. What remains is the shell entity trading on the Expert Market (PINK). As of late 2025, the market capitalization for this residual entity was approximately $1,075.00.

No recurring revenue from device sales or consumable tips exists for Viveve Medical, Inc. under its former structure. The historical revenue model relied on two components, both now defunct for the VIVE entity:

• The initial sale of the capital equipment, the Viveve System.
• The subsequent, recurring revenue from the sale of disposable treatment tips.

To give you context on the historical revenue base that is now gone, here's a look at the last reported full-year revenue figures before the asset sale effectively ended operations:

The company's last reported Trailing Twelve Months (TTM) revenue, prior to the final liquidation steps, was $6.83 Million USD, based on data ending around September 2022. That TTM figure included both equipment and consumables, which were the two primary drivers of the old revenue stream.

The breakdown of the former revenue streams, based on pre-liquidation activity, generally looked like this:

• Device Sales: Capital equipment sales, one-time purchases.
• Consumable Sales: Disposable treatment tips, the intended recurring revenue component.
• Geographic Contribution: Sales were split between a direct sales force in North America and distribution partners internationally.

Finance: draft 13-week cash view by Friday.